CRTX - Cortexyme in pact with Jefferies to sell up to $150M worth of common stock

Cortexyme (NASDAQ:CRTX) has struck an Open Market Sale Agreement with Jefferies to periodically issue and sell up to $150M of company common stock of par value $0.001 per share. The company has filed a prospectus supplement with the SEC in this regard, Cortexyme (CRTX) said in a regulatory filing on Thursday after the close. The shares to be issued under the agreement will be in line with a shelf registration statement by the company in June 2020. Cortexyme (CRTX) shares have added ~4.2% in the pre-market. The short interest in the small-cap biotech was elevated heading into the final week of trading of the year, Seeking Alpha’s Catalyst Watch noted last Friday. Read more on the updated Phase 2/3 data for the company’s Alzheimer’s candidate atuzaginstat.

For further details see:

Cortexyme in pact with Jefferies to sell up to $150M worth of common stock